Condition

Mesothelioma, Malignant

ClinicalTrials.gov condition label

Clinical trials29

Recruiting10

Common interventions25

Lead sponsors shown15

Clinical trials

29 shown

Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaNCT07126509 · 2025-12-02

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaNCT05188859 · 2024-09-01

SW-682 in Advanced Solid TumorsNCT06251310 · 2024-07-31

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionNCT06051695 · 2024-04-03

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaNCT06057935 · 2023-09-21

HTL0039732 in Participants With Advanced Solid TumoursNCT05944237 · 2023-08-02

First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.NCT06946498 · 2023-05-23

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or MesotheliomaNCT05568680 · 2023-03-30

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingNCT04981119 · 2021-10-29

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNCT04104776 · 2019-09-18

NM32-2668 in Adult Patients With Selected Advanced Solid TumorsNCT06299163 · 2024-05-01

Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid TumoursNCT05698238 · 2024-01-01

NOT_YET_RECRUITING

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin AdministrationNCT06281860 · 2023-11-24

Immunological Variables Associated to ICI Toxicity in Cancer PatientsNCT05429866 · 2022-09-01

Niraparib Efficacy in Patient With Unresectable MesotheliomaNCT05455424 · 2022-07-11

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerNCT05451849 · 2022-06-21

......SMARTEST Trial......NCT05380713 · 2022-05-03

Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural MesotheliomaNCT04823741 · 2022-02-11

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsNCT05136677 · 2022-01-25

A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)NCT05324436 · 2022-01-08

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior TherapiesNCT03546426 · 2019-12-12

ACTIVE_NOT_RECRUITING

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerNCT03907852 · 2019-04-15

ACTIVE_NOT_RECRUITING

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaNCT03654833 · 2019-01-28

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated MesotheliomaNCT03502746 · 2018-06-26

Combination of Immunotherapy and Hyperthermia in Advanced Malignant MesotheliomaNCT03393858 · 2017-12-01

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)NCT02357147 · 2015-11-03

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural MesotheliomaNCT02303899 · 2014-11-01

11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)NCT02519049 · 2014-09-01

Malignant Mesothelioma - Can we Improve Quality of LifeNCT03068117 · 2014-04-03

Common interventions

Leading sponsors

A2 Biotherapeutics Inc.2 Bristol-Myers Squibb2 Istituto Clinico Humanitas2 TCR2 Therapeutics2 Arkadiusz Z. Dudek, MD1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 Cancer Research UK1 Capital Medical University1 Dr Jean Yannis PERENTES1 Hospices Civils de Lyon1 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1 Jules Bordet Institute1 Mabpro, a.s.1 Memorial Sloan Kettering Cancer Center1 Morphotek1

Trial status mix

RECRUITING10

COMPLETED8

TERMINATED5

UNKNOWN3

ACTIVE_NOT_RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE216

PHASE112

NA3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.